

Statistical Profile

1 April 2017 to 31 March 2020



Met achievable standard
Met acceptable standard

Met achievable standard
Met acceptable standard
Failed acceptable standard

Southern Unit Consolidated 3 yr Performance Summary: 1st April 2017 to 31st March 2020												
KPI	Standard		KC62	Activity Data		National Standards						
KFI	The Percentage of	I	Source	Invited	17/18 18/19 16,468 17,187		19/20 13,425	17-20 47,080	National Standards			
Uptake	Eligible Women Who Attend for	Overall	Table A-C2	Screened	12,541	13,301	10,254	36,096	Acceptable >70%			
	Screening The Percentage of		Age 50-70	Uptake Rate (%)	76 2,715	2,933	76 2,346	7,994	Achievable >80%			
Uptake	Eligible Women	Prevalent Screen	Table A Age 45-52	Screened	1,996	2,152	1,724	5,872	Non KPI Measure of			
	Who Attend for The Percentage of		Table C1	Uptake Rate (%) Invited	73.52 10,865	73.37 11,330	73.49 8,790	73.46 30,985	Performance (prevalent was age 50-52			
Uptake	Eligible Women Who Attend for	Screen	Age 50-70	Screened Uptake Rate (%)	9,746 89.70	10,229 90.28	7,910 89.99	27,885 90.00	Incident was age 53-70)			
Referral to Assessment		Prevalent	Table A	Screened Assessed	1,996 180	2,152 175	1,724	5,872 492	Prevalent age cohort change: 45-52 from April 2017			
	The Percentage of Women Referred to Assessment	Screen	Age 45-52	Referred to Assessment Rate (%)	9.02	8.13	7.95	8.38	Acceptable <10% Achievable <7%			
		Incident Screen	Table C1	Screened Assessed	9,746 412	10,229 410	7,910 318	27,885 1,140	Incident age cohort change: 50-70 from April 2017			
			Age 50-70	Referred to Assessment Rate	4.23	4.01	4.02	4.09	Acceptable <7%			
Short Term Recall	The Percentage of Women Placed on Short Term Recall	Overall	Table T Age 50-70	(%) Screened	12,756	13,466	10,409	36,631	Achievable <5%			
				Short Term Recall Short Term Recall Rate (%)	0.01	0.00	0.01	0.01	Acceptable <0.25%			
				Screened	1,996	2,152	1,724	5,872	Achievable <0.12% Not a KPI from April 2017			
	The Rate of Invasive Cancers Detected in Eligible Women Invited and Screened	Prevalent Screen Incident Screen	Table A Age 45-52 Table C1 Age 50-70	Invasive Cancers Invasive Cancer Detection	10 5.01	7 3.25	10 5.80	27 4.60	(was age 50-52 at Acceptable >2.7/1000			
Invasive Cancer				Rate (per 1,000) Screened	9,746	10,229	7,910	27,885	Achievable >3.6/1000) Not a KPI from April 2017			
Detection				Invasive Cancers Invasive Cancer Detection	68	61	60	189	(was age 53-70 at Acceptable >3.1/1000			
				Rate (per 1,000)	6.98	5.96	7.59	6.78	Achievable >4.2/1000)			
	The Rate of Non- Invasive Cancers Detected in Eligible Women Invited and Screened	Prevalent Screen Incident	Table A Age 45-70 Table C1	Screened Non/Micro Invasive Cancers	2,074 3	3	1,800 4	6,130 10	Prevalent age cohort change: 45-70 from April 2017			
Non-Invasive Cancer				Non-Invasive Cancer Detection Rate (per 1,000)	1.45	1.33	2.22	1.63	Acceptable >0.5/1000			
Detection				Screened Non/Micro Invasive Cancers	9,746 10	10,229 8	7,910 7	27,885 25	Incident age cohort change: 50-70 from April 2017			
		Screen	Age 50-70	Non-Invasive Cancer Detection Rate (per 1,000)	1.03	0.78	0.88	0.90	Acceptable >0.6/1000			
SDR	Standardised	Prevalent & Incident	Table A-C1	Observed Expected	82 49.64	74 52.71	72 40.76	228 143.11	Not a KPI from April 2017			
	Detection Ratio	Screen	Age 45-70	SDR	1.65	1.40	1.77	1.59	(was age 50-70) New KPI from April 2017			
SDR	Standardised	Prevalent & Incident	Table A-C1	Observed Expected	54 27.30	43 28.99	46 22.42	143 78.71	(was aged 50-70)			
<15mm	Detection Ratio	Screen	Age 45-70	SDR	1.98	1.48	2.05	1.82	Acceptable >1.0 Achievable >1.4			
CDD	Standardised Detection Ratio Standardised Detection Ratio	Prevalent Screen Prevalent Screen	Table A + B	Observed Expected	14 9.80	13 11.08	12 8.31	39 29.18	New KPI from April 2017 (was aged 50-70)			
SDR			A + B Age 45-70	SDR	1.43	1.17	1.44	1.34	Acceptable >1.0 Achievable >1.4			
SDR			Table	Observed	7 5.39	7	8 4.57	22	Non KPI Measure of			
<15mm			A + B Age 45-70	Expected SDR	1.30	6.09 1.15	1.75	16.05 1.37	Performance			
SDR	Standardised Detection Ratio	Incident Screen	Table C1 Age 50-70	Observed Expected	68 39.84	61 41.64	60 32.45	189 113.93	New KPI from April 2017			
ODIC				SDR	1.71	1.47	1.85	1.66	Acceptable >1.0 Achievable >1.4			
SDR	Standardised	Incident	Table C1	Observed Expected	47 21.91	36 22.90	38 17.85	121 62.66	Non KPI Measure of			
<15mm	Detection Ratio	Screen	Age 50-70 Table	SDR Observed	2.14 11	1.57 8	2.13	1.93 29	Performance			
SDR	Standardised Detection Ratio	Prevalent Screen	A + B Age 45-52	Expected SDR	7.30 1.51	7.91			Non KPI Measure of			
SDR	Standardised	Prevalent	Table	Observed	5	5	6	16	Performance			
<15mm	Detection Ratio	Screen	A + B Age 45-52	Expected SDR	4.02 1.25	4.35 1.15	3.47 1.73	11.83 1.35				
	The Rate of Invasive Cancers <15mm Detected in Eligible Women Invited and Screened	Prevalent Screen Incident	Table A Age 45-52 Table C1	Screened Invasive Cancers <15mm	1,996 4	2,152 4	1,724 6	5,872 14	Not a KPI from April 2017 (was age 50-52 at			
Small Invasive				Small Invasive Cancer Detection Rate (per 1,000)	2.00	1.86	3.48	2.38	Acceptable >2.0/1000 Achievable >2.8/1000)			
Cancer Detection				Screened Invasive Cancers <15mm	9,746 47	10,229 36	7,910 38	27,885 121	Not a KPI from April 2017 (was age 53-70 at			
		Screen	Age 50-70	Small Invasive Cancer Detection Rate (per 1,000) 4.82 3.52 4.80			4.34	Acceptable >2.3/1000 Achievable >3.1/1000)				
				Referred for Cytology/Core	90	86	74	250	Achievable 20.1/1000)			
Non- Operative Diagnosis	Women who have a Non-Operative Diagnosis of Cancer by Cytology or Needle Histology after a Maximum of 2 Visits	Invasive Cancers	Table T Age 50-70	Invasive cancers Invasive Non-operative	90	86 100.00	74 100.00	250 100.00	Acceptable >90%			
				diagnosis Rate (%) Referred for Cytology/Core	14	15	11	40	Achievable >95%			
		Non- Invasive		Non-Invasive Cancers DCIS Non-operative	13	14	11	38	Acceptable >85%			
		Cancers		diagnosis rate (%) Screened	92.86 1,996	93.33 2,152	1,724	95.00 5,872	Achievable >90% Prevalent age cohort change:			
		Prevalent	Table A Age 45-52 Table C1	Benign Biopsies	2	1	0	3	45-52 from April 2017			
Benign Biopsy	The Rate of Benign	Screen		Benign Biopsy Rate (per 1,000)	1.00	0.46	0.00	0.51	Acceptable <1.5/1000 Achievable <1.0/1000			
	Biopsies	Incident		Screened Benign Biopsies	9,746	10,229	7,910 2	27,885 8	Incident age cohort change: 50-70 from April 2017			
		Screen	Age 50-70	Benign Biopsy Rate (per 1,000)	0.31	0.29	0.25	0.29	Acceptable <1.0/1000 Achievable <0.75/1000			
KPI	Standard			Activity Data		Local Per 17/18 18/19		17-20	National Standards			
Screen	The Percentage of			Previously Screened	12,191	12,563	9,741	34,495				
Round Length	Offered Appointment is Within 36 Months of Their Previous Screen			FOA <36m FOA <36m (%)	12,049 99	12,530 100	9,728	34,307 99	Acceptable >90%			
				Screened	12,653	13,695	10,657	37,005	Achievable 100% Acceptable standard change			
Waiting Time for Results Technical	The Percentage of Women Who are Sent Their Result Within 2 Weeks			Result <2 weeks	12,612 99.7	13,692 100.0	10,655 100.0	36,959 99.9	from April 2017 Acceptable >95%			
				Result <2 weeks (%) Screened	13,452	14,413	11,129	38,994	Achievable 100%			
Recall/	The Number of F	Repeat Exami	nations	Tech recalls/repeats	449	366	240	1,055	Acceptable <3%			
Repeat				Tech recalls/repeats (%)	3.34 718	2.54 715	2.16 562	1,995	Achievable <2% Acceptable standard change			
Waiting Time for	Percentage of Won Appointment for Ass			Offered Assessment Offered <3 weeks	664	715	4 562 1,940 from A		from April 2017			
Assessment	of Attendance for the	Screening M	lammogram	Offered <3 weeks (%) 92.5 99.9 100.0 97.2				Acceptable >98% Achievable 100%				
Waiting Time for	Percentage of W Assessment Centre	within Three	Weeks of	Assessed <3 weeks 606 673 511 1,7				1,984 1,790	Non KPI Measure of Performance			
Assessment	Attendance for the S			Assessed <3 weeks (%)	84.8	94.8	91.4	90.2	renomiance			

Met achievable standard Met acceptable standard Failed acceptable standard

Met achievable standard
Met acceptable standard
Failed acceptable standard

OBJECTIVE	Northern Ireland			BHSCT			NHSCT			SHSCT			WHSCT			Acceptable	Achieveable
	17/18	18/19	19/20	17/18	18/19	19/20	17/18	18/19	19/20	17/18	18/19	19/20	17/18	18/19	19/20		
Uptake Rate %																	
Prevalent	71.92	73.66	72.05	67.55	71.47	69.56	76.58	77.94	73.41	73.52	73.37	73.49	74.90	74.36	74.09		
Incident	89.37	89.90	89.21	88.77	88.75	89.52	89.92	91.13	87.71	89.70	90.28	89.99	89.66	90.56	89.80	<u>></u> 70%	<u>></u> 80%
Overall	75.05	76.89	76.01	71.38	74.14	74.39	78.69	80.40	76.81	76.15	77.39	76.38	78.02	78.54	78.10	-	_
Technical Recall/Repeat %	2.79	2.65	2.39	2.92	2.54	2.84	2.39	2.77	2.24	3.34	2.54	2.16	2.42	2.82	1.87	<3%	<2%
Percentage Assessed %																	
Prevalent	8.54	5.98	5.53	11.67	6.54	5.71	6.99	5.59	4.11	9.02	8.13	7.95	3.67	3.58	4.64	<10%	<7
Incident	2.90	2.54	2.52	2.76	2.01	2.14	2.99	2.15	1.93	4.23	4.01	4.02	1.81	2.37	2.74		
	0.04	0.03	0.01	0.07	0.02	0.00	0.04	0.05	0.01	0.01	0.00	0.01	0.02	0.05	0.02	<7%	<5 <0.12%
Early Recall %	0.04	0.03	0.01	0.07	0.02	0.00	0.04	0.05	0.01	0.01	0.00	0.01	0.02	0.05	0.02	<0.25%	<0.12%
Benign Biopsy Rate	4.40	4.00	0.05	4.00	0.00	0.00	4.40	0.40	0.44	4.00	0.40	0.00	0.40	0.00	0.50	4.5/4000	4.0/4.000
Prevalent	1.40	1.00	0.65	1.03	0.28	0.00	1.43	3.42	2.14	1.00	0.46	0.00	2.48	0.80	0.59	<1.5/1000	<1.0/1000
Incident	0.40	0.31	0.25	0.51	0.16	0.05	0.47	0.36	0.35	0.31	0.29	0.25	0.20	0.52	0.54	<1.0/1000	<0.75/1000
DCIS Cancer Rate																	
Prevalent	2.12	2.48	1.56	2.49	2.11	0.28	2.76	3.80	2.48	1.45	1.33	2.22	1.44	3.10	2.27	>05./1000	N/A
Incident	1.12	1.13	1.29	1.12	0.87	1.45	1.13	1.68	1.41	1.03	0.78	0.88	1.20	1.47	1.19	>=0.6/1000	N/A
Invasive Cancer Rate																	
Prevalent	4.8	3.7	4.9	5.2	3.3	4.9	3.8	5.1	4.3	5.0	3.3	5.8	5.0	3.6	4.8	>=2.70/1000	>=3.6/1000
Incident	6.4	5.7	6.5	6.4	4.9	6.1	6.0	5.5	6.0	7.0	6.0	7.6	6.2	7.0	7.0	>=3.10/1000	>=4.2/1000
Small Invasive Cancer Rate																	
Prevalent	2.4	1.7	1.6	2.1	1.4	1.7	2.4	1.7	0.9	2.0	1.9	3.5	3.5	2.0	0.6	<u>></u> 2.0	<u>≥</u> 2.8
Incident	3.8	3.1	3.5	3.4	2.5	3.3	3.0	3.2	2.6	4.8	3.5	4.8	4.4	3.5	3.8	<u>≥</u> 2.3	<u>≥</u> 3.1
Invasive Pre-operative Diagnosis Rate % Non invasive Pre- operative Diagnosis Rate	99.27	100.00	98.68	99.38	100.00	99.29	98.72	100.00	95.24	100.00	100.00	100.00	98.78	100.00	100.00	<u>≥</u> 95%	N/A
%	94.12	92.22	96.43	90.63	100.00	96.77	95.45	90.00	95.83	92.86	93.33	100.00	100.00	84.62	94.44	<u>≥</u> 95%	N/A
Roundlength ≤ 36 months	98.1	96.4	99.3	97.8	92.8	99.6	99.2	97.3	98.9	98.8	99.7	99.9	96.8	98.5	98.7	>90%	100%
Screen to Results	99.4	99.7	99.6	99.5	99.8	99.8	99.7	99.9	99.3	99.7	100.0	100.0	98.6	99.3	99.3	>95%	100%
(% ≤ 2 weeks)		30.1	00.0	00.0	00.0	33.3	0011	00.0	00.0	00			33.3	00.0	00.0	7 00 / 0	10070
Screen to Assessment (% ≤ 3 weeks) Date of offered	90.0	00.0	00.2	92.0	00.5	08.0	07.4	00.0	100.0	02.5	00.0	100.0	09.0	00.4	00.7		
appointment Date of attended	89.8	99.0	99.2	82.9	98.5	98.0	97.1	98.2	100.0	92.5	99.9	100.0	98.0	99.1	99.7	>98%	100%
appointment	89.8	99.0	99.2	76.3	93.3	90.2	91.7	94.7	92.2	84.8	94.8	91.4	90.0	89.1	96.1	N/A	N/A